Cancer Moonshot

White House Highlights National Minority Quality Forum in Progress Report on Biden Cancer Moonshot

Retrieved on:

星期三, 五月 15, 2024

CSSI, Technology policy, Lung, Doctor of Philosophy, COVID-19, Private sector, Risk, Education, Diagnosis, Breast cancer, Cancer Moonshot, Cancer, Health education, Policy, Mobile phone

The Biden Cancer Moonshot was reignited in 2022 by President Biden and First Lady Biden, who announced a call to action on cancer screening to jumpstart progress on the almost 10 million recommended cancer screenings that Americans missed during the COVID-19 pandemic.

Key Points:

The Biden Cancer Moonshot was reignited in 2022 by President Biden and First Lady Biden, who announced a call to action on cancer screening to jumpstart progress on the almost 10 million recommended cancer screenings that Americans missed during the COVID-19 pandemic.
More than 35 private sector organizations, including NMQF, have joined the Biden Cancer Moonshot, positively impacting almost one million Americans.
NMQF launched its Cancer Stage Shifting Initiative (CSSI) in response to the Biden Cancer Moonshot, with a mission to move historically excluded communities in the U.S. from disparate, late-stage diagnoses to early-stage diagnoses and treatment of cancer.
Looking forward, NMQF will continue its CSSI activities in further support of the Cancer Moonshot, bringing resources directly into the communities that need them most.

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

Retrieved on:

星期五, 五月 17, 2024

Technology policy, Episcopal conference, Booth, ACOG, FDA, Cervical cancer, Collection, Uterine cancer, Cancer Moonshot, Woman, Policy, American College, OSTP, Cancer, Birth control

According to The White House , OSTP “works to bring that idea to life by harnessing the power of science, technology, and innovation to achieve America’s great aspirations.” OSTP also supports the Cancer Moonshot, which is focused on mobilizing a national effort to end cancer.

Key Points:

According to The White House , OSTP “works to bring that idea to life by harnessing the power of science, technology, and innovation to achieve America’s great aspirations.” OSTP also supports the Cancer Moonshot, which is focused on mobilizing a national effort to end cancer.
During the meeting, Ms. Lee-Sepsick and the OSTP staff discussed the priority actions for the Cancer Moonshot, including important priorities related to cervical cancer.
Femasys intends to broaden its cancer diagnostic portfolio with an endometrial sampler for uterine cancer in the future.
The event is taking place in San Francisco’s Moscone Center May 17-19, 2024 and Femasys will be exhibiting at Booth #1413.

HealthWell Foundation to Exhibit at Upcoming Oncology Meeting

Retrieved on:

星期二, 五月 14, 2024

Insurance, Transport, McCormick Place, Patient, Survival, Clinical trial, Pharmacy, Disease, Cancer Moonshot, Contribution, Plasma protein binding, Psychotherapy, Annual general meeting, Nursing

During the meeting, HealthWell representatives will share valuable program resources from our portfolio of over 30 oncology funds to assist underinsured patients in accessing medical treatments they otherwise would not be able to afford.

Key Points:

During the meeting, HealthWell representatives will share valuable program resources from our portfolio of over 30 oncology funds to assist underinsured patients in accessing medical treatments they otherwise would not be able to afford.
As part of the Cancer Moonshot initiative, in 2024 HealthWell Foundation committed to:
Provide more than $300 million to underinsured oncology patients to offset out-of-pocket medication costs.
"We look forward to participating in this meeting each year and to educating patients, advocates, providers, and pharmacies about our life-changing work," said Alan Klein, HealthWell Foundation Chief Development Officer.
To learn more about HealthWell Foundation's robust oncology fund portfolio, visit our Disease Funds page.

Cancer Moonshot Gets a Booster Shot from This AI-Driven Clinical Research Platform

Retrieved on:

星期一, 五月 13, 2024

MANASSAS, Va., May 13, 2024 /PRNewswire-PRWeb/ -- The clinical trial landscape is marred by persistent operational inefficiencies that have only been marginally addressed by the proliferation of technology and the shift to remote trial operations. 2024 is seeing a surge in the fight against cancer, with cancer clinical trials dominating the rest. (1) Dr. Rajasimha notes, "Despite the AI revolution, digital transformation initiatives, and the advent of remote operations, the core goals of clinical trials—to assess the safety and efficacy of treatment options—remain unchanged. They are also getting increasingly inefficient, expensive, longer, and complex due to short-sighted point solutions that address specific parts of the drug development process. We need comprehensive solutions to this nagging problem - a piecemeal approach has resulted in 90% failure rate of candidate drugs in the 'valley of death' and 30% trial terminations due to poor enrollment." (2)

Key Points:

President Biden's loss of his beloved son to brain cancer in 2015 inspired the Cancer Moonshot initiative.
2024 is seeing a surge in the fight against cancer, with cancer clinical trials dominating the rest.
His commitment aligns with the audacious goals of the Whitehouse's Cancer Moonshot initiative, forging a powerful partnership towards excellence in Cancer clinical research and treatment.
Harnessing cutting-edge technologies like AI, driving breakthroughs in precision cancer treatment options, as validated by recent NIH research.

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association

Retrieved on:

星期二, 四月 30, 2024

“The realization that this transformation of MHC- to MHC+ could rescue exhausted or immune-evaded T cells was the basis of our Cancer Moonshot announced in 2016 .

Key Points:

“The realization that this transformation of MHC- to MHC+ could rescue exhausted or immune-evaded T cells was the basis of our Cancer Moonshot announced in 2016 .
I very much look forward to elaborating on the details with Dr. Sam Chang at the AUA conference,” said Dr. Patrick Soon-Shiong.
Hosting Dr. Soon-Shiong will be Dr. Sam S. Chang, M.D., Professor of Urology and Chief Surgical Officer of the Vanderbilt Ingram Cancer Center.
Dr. Chang was a principal investigator for ImmunityBio’s QUILT 3.032 study, which produced the data on which the FDA approval was based.

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

Retrieved on:

星期四, 四月 25, 2024

View the full release here: https://www.businesswire.com/news/home/20240424428572/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20240424428572/en/
In NSCLC patients who relapsed or were refractory to checkpoint inhibitors, ANKTIVA was administered together with the same checkpoint inhibitor.
The addition of ANKTIVA resulted in the rescue of the checkpoint therapy efficacy, with significant prolongation of overall survival.
This prolongation of survival in NSCLC following checkpoint failure is consistent with ImmunityBio’s findings of durable complete responses following BCG failure in NMIBC.
According to the American Cancer Society, lung cancer is the second most common cancer in the U.S.

HealthWell Foundation Invited to Participate in The White House Minority Health Forum

Retrieved on:

星期四, 四月 18, 2024

Technology policy, Forum, Cancer Moonshot, Federation, Policy, Patient, Physician, Private sector, Pharmaceutical industry

GERMANTOWN, Md., April 18, 2024 /PRNewswire/ -- The HealthWell Foundation®, an independent non-profit charitable organization that provides financial assistance for underinsured Americans, is honored to announce its participation in the White House Minority Health Forum taking place today, April 18, 2024. Alan Klein, HealthWell Foundation Chief Development Officer, will attend the Forum and participate in the breakout session: Making Innovation & Research Work for Everyone.

Key Points:

GERMANTOWN, Md., April 18, 2024 /PRNewswire/ -- The HealthWell Foundation®, an independent non-profit charitable organization that provides financial assistance for underinsured Americans, is honored to announce its participation in the White House Minority Health Forum taking place today, April 18, 2024.
Alan Klein, HealthWell Foundation Chief Development Officer, will attend the Forum and participate in the breakout session: Making Innovation & Research Work for Everyone.
The White House Minority Health Forum aims to highlight progress, discuss challenges, and identify new actions from the federal government and the private sector to improve health outcomes and reduce health inequities.
"We were honored by The White House Office of Science and Technology Policy's invitation to take part in this critical discussion among key health leaders," said HealthWell Foundation Board Chair, David L. Knowlton.

White House declares April 2024 as Cancer Prevention and Early Detection Month

Retrieved on:

星期五, 三月 29, 2024

Health, Organization, Partnership, Cancer, Cancer Moonshot, Risk, Family, Birth control

Alexandria, Va., March 29, 2024 (GLOBE NEWSWIRE) -- The White House today issued an official presidential proclamation declaring April 2024 as the inaugural National Cancer Prevention and Early Detection Month.

Key Points:

Alexandria, Va., March 29, 2024 (GLOBE NEWSWIRE) -- The White House today issued an official presidential proclamation declaring April 2024 as the inaugural National Cancer Prevention and Early Detection Month.
The designation of National Cancer Prevention and Early Detection Month is a collaborative effort spearheaded by the Prevent Cancer Foundation and supported by 84 organizations.
This awareness month is a critical step toward reducing the impact of cancer on individuals, families and communities across the U.S.
“I’m immensely proud of the Foundation for leading a herculean effort in partnership with the White House Cancer Moonshot team to officially recognize April 2024 as the first-ever National Cancer Prevention and Early Detection Month,” says Jody Hoyos, CEO of the Prevent Cancer Foundation.
Highlighting progress: Celebrating the tremendous progress made in cancer research and the development of innovative prevention and early detection strategies driven forward by the Cancer Moonshot.

123 Leading Organizations Urge President Biden: Act Now to Eliminate Menthol Cigarettes

Retrieved on:

星期四, 三月 21, 2024

Health, Organization, Tobacco industry, The Washington Post, Tobacco, Health equity, Public, African Americans, Research, Delays, Cancer, Death, Cancer Moonshot, Woman, Smoking, Administration, FDA

Act now to eliminate menthol cigarettes," the ad states.

Key Points:

Act now to eliminate menthol cigarettes," the ad states.
Menthol cigarettes are a "starter product" for youth because menthol cools and numbs the throat, masking the harshness of tobacco smoke.
Researchers estimate that prohibiting menthol cigarettes will save up to 654,000 lives within 40 years, including 255,000 Black lives.
Given these enormous benefits, the Biden Administration has an obligation to issue the final rules prohibiting menthol cigarettes and flavored cigars without further delay.

MEDITECH to Spotlight Intelligent Interoperability at HIMSS24

Retrieved on:

星期四, 三月 7, 2024

As a longtime interoperability leader and advocate, MEDITECH is once again excited to feature its latest interoperability innovations in the HIMSS Interoperability Showcase.

Key Points:

As a longtime interoperability leader and advocate, MEDITECH is once again excited to feature its latest interoperability innovations in the HIMSS Interoperability Showcase.
MEDITECH will present its interoperability strategy at the Interoperability Showcase Spotlight Theater on Wednesday, March 13 at 11:15 a.m. in the “Intelligent Interoperability” session.
“Intelligent interoperability opens the doors to innovation by leveraging the flexibility and scalability of the cloud , along with modern and open data standards like SMART apps and FHIR APIs.
MEDITECH will also share its Canadian interoperability strategy at the “Achieving a Collaborative Approach to Meaningful Interoperability Across Canada” session.